Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine

• Status: Completed
• Trial end date: 2016-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Sugammadex may prevent residual neuromuscular blockade by providing rapid reversal at the end of the operation. Our goal is to compare the half-dose use of sugammadex for reversing residual blockade after administration of neostigmine and atropine to the routine use of reversal medication.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
• Treatments: Neostigmine

Criteria

Inclusion Criteria:

• Inclusion criteria:

• 40 and 65 years of age,

• American Society of Anesthesiologists Physical Status (ASA-PS) of 3 and 4,

• Elective lower gastrointestinal tumor resection surgeries,

• Supine positioning,

• Surgery requiring use of general anesthesia and muscle relaxation,

• Use of inhalational agent of sevoflurane anesthesia,

• Surgical duration of about three to six hours.

Exclusion Criteria:

• History of known or suspected neuromuscular disease,

• History of renal or hepatic dysfunction,

• Hyperkalemia,

• Patients receiving antibiotics, anticonvulsants, or magnesium,

• History of stroke,

• History of glaucoma,

• History of pregnancy or breastfeeding,

• Suspicion of abdominal infection or sepsis,

• Suspected history of malignant hyperthermia,

• An allergy to medications used during general anesthesia